Ginkgo Bioworks Holdings Inc.

Ginkgo Bioworks Holdings Inc.

World Rank (Aug-2026)
12796
Market Cap (Aug-2026)
0.437 Billion USD
Market Cap (Mar-08-2026)
0.403 Billion USD
World Rank (Jan-05-2024)
4,113
Market Cap (Jan-05-2024)
3.262 Billion USD
World Rank (Jul-30-2023)
2,929
Market Cap (Jul-30-2023)
5.089 Billion USD
Company Rank in Country in 2023
Rank in USA in July-2023 is 969
Headquarters Country
USA
Nasdaq / NYSE Code
DNA
Employee Count
8,200
Employee Count as of Date
As on 2022
Headquarters City/State
Massachusetts
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
170 Million USD
Annual Operating Income in USD
-315 Million USD
Annual Net Income in USD
-313 Million USD
Annual Results for Period Ending
For year ending December-2025
Total Assets in USD
1,120 Million USD
Total Liabilities in USD
611 Million USD
Total Equity in USD
509 Million USD
Balance Sheet for Period Ending
As of December-2025
Business Sector
Biotechnology
Company Website
GINKGO BIOWORKS HOLDINGS, INC.
Company Profile

GINKGO BIOWORKS HOLDINGS, INC.is a Biotechnology Holding company, and its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Headquarters is in USA.

As on Dec-2021, Microsoft has 182,268 employees.

GINKGO BIOWORKS HOLDINGS, INC Annual Revenue in 2021 was 365,817 Million USD and it's Total Net Sales in 2021 was 274,515 Million USD.

Total Assets as on Dec-2021 was 2,070 Million USD.

Annual Results Summary

GINKGO BIOWORKS HOLDINGS, INC. - Yearly Revenue and Net Income - in Million USD:

Year - EndingRevenueOperating IncomeNet Income
Dec-2022477-2,208 (Loss)-2,104 (Loss)
Dec-2021313-1,828 (Loss)-1,888 (Loss)
Dec-202076-137 (Loss)-126 (Loss)
Dec-201954-71 (Loss)-119 (Loss)
Balance Sheet Summary

Total Assets as on Dec-2022 was 2,539 Million USD.

Total Liabilities as on Dec-2022 was 803 Million USD.

Total Equity as on Dec-2022 was 1,736 Million USD.

IPO Year
2021
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Biological Products (No Diagnostic Substances)

Share